Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)
Georgina V. Long(The University of Sydney), Jeffrey S. Weber(NYU Langone Health), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Michael P. Brown(South Australia Pathology), Jacob Schachter, Michael Schenker(Sorbonne Université), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Jacopo Pigozzo(Istituto Oncologico Veneto), Thomas Eigentler(University Children's Hospital Tübingen), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Veerle de Pril(Inserm), Jean‐Jacques Grob(Aix-Marseille Université), Shahneen Sandhu(The University of Melbourne), Alexander Menzies(The University of Sydney), Jessica C. Hassel(German Cancer Research Center), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), James Larkin(Trinity College Dublin), Victoria Atkinson(The University of Queensland), Matteo S. Carlino(The University of Sydney), Andrew Haydon(The Alfred Hospital), Helen Gogas(National and Kapodistrian University of Athens), Hao Tang(Hainan University), Caroline Robert(Institut Gustave Roussy), Tuba Öcek Baş(Bristol-Myers Squibb (United States)), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sandra Re(Bristol-Myers Squibb (United States)), Marcus O. Butler(University of Toronto)
Cited by 36
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k